ArticleInternal and emergency medicine2026
Respiratory function, functional capacity, dyspnea, and sleep quality in young adults using the IQOS heated tobacco product: a matched cross-sectional study.
Article in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This matched cross-sectional study compared respiratory function, respiratory muscle strength, functional exercise capacity, dyspnea, and sleep quality between young IQOS users and matched control subjects. This study involved 31 young adult IQOS users and 31 age/sex/body mass index-matched never-tobacco users who underwent a standardized testing protocol during a single visit. Spirometry, maximal inspiratory pressure (MIP), 6-min walk test (6MWT), modified Medical Research Council (mMRC) dyspnea scale, modified Borg Scale (mBorg), and Pittsburgh Sleep Quality Index (PSQI) scores were compared. While mean resting lung functions were similar between groups (all p > 0.05), IQOS users had shorter 6MWT distances (591.1 [580.2 - 638.4] meters vs. 626.0 [600.5 - 683.8] meters, p = 0.003, r = 0.53) and higher mMRC dyspnea scores (median mMRC Grade = 1 (0-1) in IQOS users vs 0 (0-0) in controls, p < 0.001, r = 0.62), higher mBorg dyspnea scores at the end of the 6MWT (median end-6MWT mBorg rating scale 1 [0-2] vs 0 [0-1], p = 0.001, r = 0.57), and poor sleep quality (PSQI global score 6.32 ± 2.63 vs 4.58 ± 1.61, p = 0.012, r = 0.45). Additionally, while MIP values tended toward being lower in IQOS users, these differences were statistically nonsignificant (p = 0.090). In conclusion, young exclusive IQOS users showed lower functional exercise capacity, greater dyspnea, and poorer sleep quality than matched never-users despite comparable resting spirometry, and these hypothesis-generating findings warrant longitudinal evaluation with biochemical exposure verification.
Indexed as
Identifiers
42848285What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.